PotM: Pyridyldithiols as Precursors for Disulfide-Based (Self-Immolative) Linkers

PotM: Pyridyldithiols as Precursors for Disulfide-Based (Self-Immolative) Linkers

Published on 15/06/2021

Read on to find out more about Iris Biotech’s Linkerology® portfolio including substituted pyridyldithiols as building blocks for the reversible chemical conjugation to sulfhydryls.

The type of linkage between a payload and a biomolecule can either be permanent or cleavable under certain well-defined circumstances. As payloads are typically highly cytotoxic, it would be fatal if they would be released from their carrier during circulation in plasma. Hence, the linker part should be stable to conditions like pH, redox potential or presence of proteases in plasma. However, at the desired location, e. g. after internalization, it is favorable that the linker is fragmentizing in order to release the drug molecule, ideally in a traceless manner.

Besides dipeptidic linkers (Val-Cit, Val-Ala), glucuronic acid capped linkers or chinoidic variations of the trimethyl lock, one approach to introduce a cleavable linker is the incorporation of a disulfide bond. Disulfides are stable at physiological pH during circulation due to the low reducing potential of blood. In contrast, the cytosol provides a significantly more reducing environment compared to the extracellular milieu, and the intracellular concentration of reducing agents such as glutathione (GSH) is typically 1000-fold greater, with the reductive potential in cancer cells being even higher.

Thus, disulfide-containing constructs represent versatile and effective vehicles for the delivery of bioactive molecules to their cellular targets and subsequent reductive release of the cargo.

For ease of synthesis, Iris Biotech offers pyridyl disulfides as building blocks for the preparation of disulfide-based self-immolative linkers. Pyridyl disulfides undergo a disulfide exchange reaction with sulfhydryl groups to form disulfide bonds over a broad pH range also suitable for physiological pH. During the reaction, a disulfide exchange occurs between the biomolecule’s thiol group and the reagent’s 2-pyridyldithiol group. As a result, pyridine-2-thione is released, which can be followed spectrophotometrically (λmax = 343 nm) to monitor the progress of the reaction. The p-nitrophenylcarbonate activating group reacts preferably with amines or other nucleophiles and allows further derivatization, e.g. with the desired drug molecule.

 

Chemical conjugation of a pyridyldithiol to a sulfhydryl substituted biomolecule.

The variation in the linker’s chemical composition (disulfide ethoxycarbonyl-based (SSE) in the case of RL-3500 vs. disulfide benzyloxycarbonyl-based (SSB) for RL-3550) results in chemically tunable kinetics of the self-immolative cleavage due to different response rates towards GSH, showing higher rates for SSB-based self-immolative linkers compared to SSE-based ones. Thus, the choice of the linker allows the fine-tuning of the cleavage speed and payload release.

 

 

 

Disulfide-based self-immomlative linkers either based on an intramolecular cyclization cascade mechanism or an 1,6-elimination.

 

References:

  • Disulfide-Based Self-Immolative Linkers and Functional Bioconjugates for Biological Applications; Z. Deng, J. Hu and S. Liu; Macromol Rapid Commun 2020; 41: e1900531. https://doi.org/10.1002/marc.201900531

  • Stabilizing p-Dithiobenzyl Urethane Linkers without Rate-Limiting Self-Immolation for Traceless Drug Release; Y. Zheng, Y. Shen, X. Meng, Y. Wu, Y. Zhao and C. Wu; ChemMedChem 2019; 14: 1196-1203. https://doi.org/10.1002/cmdc.201900248

  • Reduction-Triggered Transformation of Disulfide-Containing Micelles at Chemically Tunable Rates; Z. Deng, S. Yuan, R. X. Xu, H. Liang and S. Liu; Angew Chem Int Ed Engl 2018; 57: 8896-8900. https://doi.org/10.1002/anie.201802909

  • Modulated Fragmentation of Proapoptotic Peptide Nanoparticles Regulates Cytotoxicity; T. Suma, J. Cui, M. Mullner, S. Fu, J. Tran, K. F. Noi, Y. Ju and F. Caruso; J Am Chem Soc 2017; 139: 4009-4018. https://doi.org/10.1021/jacs.6b11302

  • An oral redox-sensitive self-immolating prodrug strategy; T. Sun, A. Morger, B. Castagner and J. C. Leroux; Chem Commun (Camb) 2015; 51: 5721-4. https://doi.org/10.1039/c5cc00405e

  • Discovery of an SSTR2-Targeting Maytansinoid Conjugate (PEN-221) with Potent Activity in Vitro and in Vivo; B. H. White, K. Whalen, K. Kriksciukaite, R. Alargova, T. Au Yeung, P. Bazinet, A. Brockman, M. DuPont, H. Oller, C. A. Lemelin, P. Lim Soo, B. Moreau, S. Perino, J. M. Quinn, G. Sharma, R. Shinde, B. Sweryda-Krawiec, R. Wooster and M. T. Bilodeau; Journal of medicinal chemistry 2019; 62: 2708-2719. https://doi.org/10.1021/acs.jmedchem.8b02036

  • Biomarker-Based Metabolic Labeling for Redirected and Enhanced Immune Response; S. Li, B. Yu, J. Wang, Y. Zheng, H. Zhang, M. J. Walker, Z. Yuan, H. Zhu, J. Zhang, P. G. Wang and B. Wang; ACS Chem Biol 2018; 13: 1686-1694. https://doi.org/10.1021/acschembio.8b00350

  • Conjugation Chemistry-Dependent T-Cell Activation with Spherical Nucleic Acids; K. Skakuj, S. Wang, L. Qin, A. Lee, B. Zhang and C. A. Mirkin; J Am Chem Soc 2018; 140: 1227-1230. https://doi.org/10.1021/jacs.7b12579

  • Development of Efficient Chemistry to Generate Site-Specific Disulfide-Linked Protein- and Peptide-Payload Conjugates: Application to THIOMAB Antibody-Drug Conjugates; J. D. Sadowsky, T. H. Pillow, J. Chen, F. Fan, C. He, Y. Wang, G. Yan, H. Yao, Z. Xu, S. Martin, D. Zhang, P. Chu, J. Dela Cruz-Chuh, A. O'Donohue, G. Li, G. Del Rosario, J. He, L. Liu, C. Ng, D. Su, G. D. Lewis Phillips, K. R. Kozak, S. F. Yu, K. Xu, D. Leipold and J. Wai; Bioconjug Chem 2017; 28: 2086-2098. https://doi.org/10.1021/acs.bioconjchem.7b00258

  • Modulated Fragmentation of Proapoptotic Peptide Nanoparticles Regulates Cytotoxicity; T. Suma, J. Cui, M. Mullner, S. Fu, J. Tran, K. F. Noi, Y. Ju and F. Caruso; J Am Chem Soc 2017; 139: 4009-4018. https://doi.org/10.1021/jacs.6b11302

  • Design, synthesis, and evaluation of water-soluble morpholino-decorated paclitaxel prodrugs with remarkably decreased toxicity; S. Feng, K. Chen, C. Wang, X. Jiang, H. Dong, Z. Gong and K. Liu; Bioorg Med Chem Lett 2016; 26: 3598-602. https://doi.org/10.1016/j.bmcl.2016.06.012

  • An immunosuppressive antibody-drug conjugate; R. E. Wang, T. Liu, Y. Wang, Y. Cao, J. Du, X. Luo, V. Deshmukh, C. H. Kim, B. R. Lawson, M. S. Tremblay, T. S. Young, S. A. Kazane, F. Wang and P. G. Schultz; J Am Chem Soc 2015; 137: 3229-32. https://doi.org/10.1021/jacs.5b00620

  • A small-molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors; N. Krall, F. Pretto, W. Decurtins, G. J. Bernardes, C. T. Supuran and D. Neri; Angew Chem Int Ed Engl 2014; 53: 4231-5. https://doi.org/10.1002/anie.201310709

  • Multifunctionalization of magnetic nanoparticles for controlled drug release: a general approach; A. Latorre, P. Couleaud, A. Aires, A. L. Cortajarena and A. Somoza; Eur J Med Chem 2014; 82: 355-62. https://doi.org/10.1016/j.ejmech.2014.05.078

  • Application of a water-soluble pyridyl disulfide amine linker for use in Cu-free click bioconjugation; J. D. Thomas, T. R. Burke; Tetrahedron Lett. 2011; 52(33): 4316-4319. https://doi.org/10.1016/j.tetlet.2011.06.042

  • Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters; E. A. Dubikovskaya, S. H. Thorne, T. H. Pillow, C. H. Contag and P. A. Wender; Proc Natl Acad Sci U S A 2008; 105: 12128-33. https://doi.org/10.1073/pnas.0805374105

 

 

Related Products
    1. OPSS-OpNC
      OPSS-OpNC

      Product code: RL-3500

      Starting at $236.25

    2. OPSS-Bzl-OpNC
      OPSS-Bzl-OpNC

      Product code: RL-3550

      Starting at $236.25